Your browser does not support JavaScript!
Logo de Labiotech.eu

Labiotech.eu Source d'actualité

Une actualité de Labiotech.eu a été ajouté(e)
Hier à 08:34
Zealand Pharma’s drug for rare metabolic disease smashes phase III
After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide drug improved blood sugar control in infants with the rare disease congenital hyperinsulinemia in a phase III...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 4 jours
Meet the Future Makers of Labiotech
Following our recent acquisition by Inova, our team is expanding! We’re very excited to welcome three new hires to join our international team: Jim, former Editor at DairyReporter, is joining us as...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 4 jours
F2G enlists Shionogi to bring antifungal treatment to Europe and Asia
The UK company F2G Ltd. has announced a strategic collaboration with Japanese pharmaceutical company Shionogi & Co. Ltd. to develop and commercialize olorofim, an antifungal treatment for invasive...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 4 jours
Evotec, Sernova in partnership to develop beta cell diabetes therapy
Evotec and Sernova are set to join forces to advance a beta cell replacement therapy to treat insulin-dependent diabetes. As part of the deal, Evotec will make a €20M equity investment in...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 6 jours
Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags
The stock price of the French Covid-19 vaccine maker Valneva has been knocked down by 20% as the company faces losing a supply contract with the European Commission. Despite receiving a glowing...
www.labiotech.eu
Charger plus d'actualités

Informations juridiques
SIREN / SIRET - DE Labiotech

Adresse
Berlin Berlin DE Allemagne